151. Upregulation of neuronal astrocyte elevated gene-1 protects nigral dopaminergic neurons in vivo.
- Author
-
Leem E, Kim HJ, Choi M, Kim S, Oh YS, Lee KJ, Choe YS, Um JY, Shin WH, Jeong JY, Jin BK, Kim DW, McLean C, Fisher PB, Kholodilov N, Ahn KS, Lee JM, Jung UJ, Lee SG, and Kim SR
- Subjects
- Animals, Astrocytes pathology, Disease Models, Animal, Dopaminergic Neurons pathology, Humans, Membrane Glycoproteins genetics, Mice, Oxidopamine adverse effects, Oxidopamine pharmacology, Parkinson Disease, Secondary chemically induced, Parkinson Disease, Secondary genetics, Parkinson Disease, Secondary metabolism, Parkinson Disease, Secondary pathology, Ras Homolog Enriched in Brain Protein genetics, Ras Homolog Enriched in Brain Protein metabolism, Substantia Nigra pathology, Apoptosis, Astrocytes metabolism, Dopaminergic Neurons metabolism, Membrane Glycoproteins biosynthesis, Substantia Nigra metabolism, Up-Regulation
- Abstract
The role of astrocyte elevated gene-1 (AEG-1) in nigral dopaminergic (DA) neurons has not been studied. Here we report that the expression of AEG-1 was significantly lower in DA neurons in the postmortem substantia nigra of patients with Parkinson's disease (PD) compared to age-matched controls. Similarly, decreased AEG-1 levels were found in the 6-hydroxydopamine (6-OHDA) mouse model of PD. An adeno-associated virus-induced increase in the expression of AEG-1 attenuated the 6-OHDA-triggered apoptotic death of nigral DA neurons. Moreover, the neuroprotection conferred by the AEG-1 upregulation significantly intensified the neurorestorative effects of the constitutively active ras homolog enriched in the brain [Rheb(S16H)]. Collectively, these results demonstrated that the sustained level of AEG-1 as an important anti-apoptotic factor in nigral DA neurons might potentiate the therapeutic effects of treatments, such as Rheb(S16H) administration, on the degeneration of the DA pathway that characterizes PD.
- Published
- 2018
- Full Text
- View/download PDF